🕵️ Crescent Biopharma, Inc. ($CBIO)
SEC insider & ownership activity, last 12 months · CIK 1253689 · every row links its SEC filing
Over the last 12 months insiders sold $1.2M against $40.0M of open-market buying. Fairmount Funds Management LLC bought $40.0M (Dec–Jul). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $40.0M (4 lots) · 7 sellers, $1.2M (7 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 4 | $40.0M | 0 | – | Jul 16, 2026 |
| Joshua T. Brumm | 0 | – | 1 | $761K | Jun 22, 2026 |
| McNeill Jonathan | 0 | – | 1 | $370K | Jun 22, 2026 |
| Pinkas Jan | 0 | – | 1 | $23K | Jun 22, 2026 |
| Im Ellie Eunkyung | 0 | – | 1 | $22K | Jun 22, 2026 |
| Bispham Barbara Harlin | 0 | – | 1 | $22K | Jun 22, 2026 |
| Scalzo Richard William | 0 | – | 1 | $20K | Jun 22, 2026 |
| Lynch Ryan | 0 | – | 1 | $8K | Jun 22, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Peter Harwin | 16.5% | 13D | Jul 16, 2026 | filing ↗ | |
| Fairmount Funds Management LLC | 16.5% | 13D | Jul 16, 2026 | filing ↗ | |
| Tomas Kiselak | 16.5% | 13D | Jul 16, 2026 | filing ↗ | |
| Fairmount Healthcare Fund II L.P. | 16.5% | 13D | Jul 16, 2026 | filing ↗ | |
| FMR LLC | 15.0% | 13G | Feb 5, 2026 | filing ↗ | |
| Abigail P. Johnson | 15.0% | 13G | Feb 5, 2026 | filing ↗ | |
| 1GLOBE Capital LLC | 10.3% | 13G | Oct 14, 2025 | filing ↗ | |
| Jiaqiang Li | 10.3% | 13G | Oct 14, 2025 | filing ↗ | |
| BVF Partners L P/IL | 10.0% | 13G | Aug 14, 2025 | filing ↗ | |
| BVF INC/IL | 10.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Co-Investment Holdings III, LLC | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners EG, L.P. | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management III, LLC | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management EG, LLC | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| Nimish Shah | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| Bong Y. Koh | 9.5% | 13G | Feb 17, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 9.4% | 13G | Aug 14, 2025 | filing ↗ | |
| Forgrowth III Pa B.v. | 6.1% | 13G | Dec 11, 2025 | filing ↗ | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 6.1% | 13G | Dec 11, 2025 | filing ↗ | |
| Forbion Growth III Management B.V. | 6.1% | 13G | Dec 11, 2025 | filing ↗ | |
| Balyasny Asset Management L.P. | 5.5% | 13G | May 15, 2026 | filing ↗ | |
| BAM GP LLC | 5.5% | 13G | May 15, 2026 | filing ↗ | |
| Balyasny Asset Management Holdings LP | 5.5% | 13G | May 15, 2026 | filing ↗ | |
| Dames GP LLC | 5.5% | 13G | May 15, 2026 | filing ↗ | |
| Dmitry Balyasny | 5.5% | 13G | May 15, 2026 | filing ↗ | |
| Vestal Point Capital, LP | 5.4% | 13G | Feb 17, 2026 | filing ↗ | |
| Ryan Wilder | 5.4% | 13G | Feb 17, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.1% | 13G | Aug 14, 2025 | filing ↗ | |
| BVF I GP LLC | 5.1% | 13G | Aug 14, 2025 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Other events (8.01) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Earnings (2.02) | Jul 14, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 2, 2026 | filing ↗ |
| Earnings (2.02) | Apr 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 29, 2026 | filing ↗ |
| Earnings (2.02) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |
| Material agreement (1.01) | Dec 2, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Dec 2, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 2, 2025 | filing ↗ |
| Other events (8.01) | Dec 2, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 2, 2025 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Earnings (2.02) | Jul 29, 2025 | filing ↗ |
| Officer/director changes (5.02) | Jul 29, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 29, 2025 | filing ↗ |